Compare HubSpot Inc (HUBS) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HubSpot Inc vs GeneDx Holdings Corp — how do they compare? HubSpot Inc trades at $224.72 (market cap $11.84B), while GeneDx Holdings Corp trades at $60.5 (market cap $1.80B). The key difference: HubSpot Inc is far larger — about 6.6× GeneDx Holdings Corp's market cap. Which is the better fit depends on your goals.
| HUBS | WGS | |
|---|---|---|
Market Cap | $11.84B | $1.80B |
Sector | Technology | Technology |
52-Week High | $560.90 | $167.51 |
52-Week Low | $170.39 | $34.51 |
Enterprise Value | $10.39B | $1.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HubSpot (HUBS) trades at $231.36, up 3.17% with strong technical momentum and bullish moving averages. The company demonstrates robust revenue growth, reaching $3.13B in 2025 with expanding profit margins. Recent earnings consistently beat expectations, and analyst sentiment remains overwhelmingly positive with 81% buy ratings. Technical indicators show the stock approaching resistance at $232 with RSI levels suggesting potential overbought conditions.
HUBS presents compelling growth prospects with accelerating AI integration and customer expansion, though elevated valuation metrics and competitive pressures warrant caution. The stock's 14% upside to consensus target of $264.06 reflects optimism about continued execution, but investors should monitor margin sustainability and market volatility risks in the software sector.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% amid a bearish technical signal and negative profitability. Recent earnings showed a Q1 2026 miss after two prior beats, with revenue growth but widening losses projected for 2026. The stock faces significant headwinds from multiple securities class action lawsuits alleging misrepresentations, with a deadline of August 3, 2026.
Despite a high analyst buy consensus (90.9%) and a $75.40 price target implying 24% upside, risks are elevated due to litigation, negative margins, and a high EV/EBITDA of 161.17. The upcoming Q2 2026 results on August 3 will be critical for investor confidence, but the legal overhang and fundamental challenges suggest cautious near-term outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
